Open access
Open access
Powered by Google Translator Translator

Internal Medicine

Opinion | Tocilizumab in COVID-19 therapy: who benefits, and how? – the researchers suggest that maybe IL-6 inhibitors should be given only to patients with high IL-6.

23 Jul, 2021 | 10:51h | UTC

Tocilizumab in COVID-19 therapy: who benefits, and how? – The Lancet

Related: A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19. AND M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”. AND RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes AND Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less. AND M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”.

 


Secondary sclerosing cholangitis: an emerging complication in critically ill COVID-19 patients.

23 Jul, 2021 | 10:47h | UTC

Secondary sclerosing cholangitis: an emerging complication in critically ill COVID-19 patients – Intensive Care Medicine

 


How the Delta variant achieves its ultrafast spread – “Viral load is roughly 1,000 times higher in people infected with the Delta variant than those infected with the original coronavirus strain, according to a study in China”.

23 Jul, 2021 | 10:46h | UTC

How the Delta variant achieves its ultrafast spread – Nature

Original study: Study shows the viral loads in the Delta infections are ~1000 times higher than those in the earlier strain infections on the day when viruses are firstly detected.

 


What are the Delta, Gamma, Beta and Alpha Covid variants?

23 Jul, 2021 | 10:45h | UTC

What are the Delta, Gamma, Beta and Alpha Covid variants? – BBC

Related: Increased transmissibility and global spread of SARS-CoV-2 variants of concern – “Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)”. AND WHO renames COVID-19 variants with the Greek alphabet (i.e., Alpha, Beta, Gamma, etc), making them simple, easy to say and remember. The naming system aims to prevent calling COVID-19 variants by the places where they are detected, which is stigmatizing & discriminatory.

 


CDC releases new guidelines for the treatment of sexually transmitted infections.

23 Jul, 2021 | 10:41h | UTC

Table of Contents: Sexually Transmitted Infections Treatment Guidelines, 2021

Guideline: Sexually Transmitted Infections Treatment Guidelines, 2021 – Centers for Disease Control and Prevention

Related (just released): WHO Guidelines for the management of symptomatic sexually transmitted infections.

 

Commentary on Twitter (thread – click for more)

 


New series from The Lancet: Physical Activity 2021.

23 Jul, 2021 | 10:37h | UTC

Homepage: Physical Activity 2021 – The Lancet (free registration required for all articles)

Summary and commentary: Experts call for immediate action to ensure physical activity is built into everyday lives – News Medical

 

Commentary on Twitter (thread – click for more)

 


Position Statement on Endomyocardial Biopsy.

23 Jul, 2021 | 10:33h | UTC

Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy

 

Commentary on Twitter

 


Review: Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit.

23 Jul, 2021 | 10:30h | UTC

Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review – Critical Care

 


Review: Ethics in extracorporeal life support.

23 Jul, 2021 | 10:29h | UTC

Ethics in extracorporeal life support: a narrative review – Critical Care

 


RCT: Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV.

23 Jul, 2021 | 10:25h | UTC

Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Dolutegravir Confirmed as Effective Second-Line HIV Therapy; Recycling Tenofovir Noninferior to Zidovudine – Medscape (free registration required)

 


Review: The hemostatic and thrombotic complications of liver disease.

23 Jul, 2021 | 10:23h | UTC

The Hemostatic and Thrombotic Complications of Liver Disease – European Journal of Haematology

 


Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed.

22 Jul, 2021 | 11:16h | UTC

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant – New England Journal of Medicine

Commentaries: Study Finds Pfizer And AstraZeneca Vaccines Effective Against The Delta Variant — As Long As You Get Both Doses – Forbes AND Pfizer’s COVID-19 vaccine works very well against the Delta variant — but only after 2 doses – Insider

Related: [Preprint] 2 doses of Covid vaccines (Pfizer-BioNTech or Oxford-AstraZeneca) highly effective against hospitalization from Delta variant. AND Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. AND Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta.

 

Commentary on Twitter

 


COVID-19 antibodies persist at least nine months after infection – “98.8 percent of people infected in February/March showed detectable levels of antibodies in November”.

22 Jul, 2021 | 11:14h | UTC

News release: COVID-19 antibodies persist at least nine months after infection – Imperial College London

Original study: SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo’ – Nature Communications

 


RCT: Dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 – safe, but no statistically significant risk reduction in organ dysfunction or death.

22 Jul, 2021 | 11:08h | UTC

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Diabetes & Endocrinology

Commentary: Dapagliflozin in patients with COVID-19: truth or dare – The Lancet Diabetes & Endocrinology

 


Analysis finds benefits of COVID-19 vaccination outweigh risks of rare cases of myocarditis.

22 Jul, 2021 | 11:05h | UTC

News release: Study finds benefits of COVID-19 vaccination outweigh risks of rare cases of myocarditis – American Heart Association

Original study: Myocarditis with COVID-19 mRNA Vaccines – Circulation

Commentary: Myocarditis and COVID-19 Vaccines: New Review Tackles Knowns, Unknowns – TCTMD

 

Commentary on Twitter

 


Opinion | The benefits of a COVID vaccine far outweigh the small risk of treatable heart inflammation.

22 Jul, 2021 | 10:57h | UTC

The benefits of a COVID vaccine far outweigh the small risk of treatable heart inflammation – The Conversation

 


WHO Guidelines for the management of symptomatic sexually transmitted infections.

22 Jul, 2021 | 10:54h | UTC

Guidelines for the management of symptomatic sexually transmitted infections – World Health Organization

News release: Launch WHO guidelines for the management of symptomatic sexually transmitted infection – World Health Organization

 

Commentary on Twitter

 


Review: The routes of administration for acute postoperative pain medication.

22 Jul, 2021 | 10:46h | UTC

The Routes of Administration for Acute Postoperative Pain Medication – Pain and Therapy

 


A Narrative Review on the Role of Staphylococcus aureus Bacteriuria in S. aureus Bacteremia.

22 Jul, 2021 | 10:37h | UTC

A Narrative Review on the Role of Staphylococcus aureus Bacteriuria in S. aureus Bacteremia – Open Forum Infectious Diseases

 

Commentary on Twitter

 


Guideline on the management of IgE-mediated food allergies.

22 Jul, 2021 | 10:34h | UTC

Update of the S2k guideline on the management of IgE-mediated food allergies – Allergologie Select

 


RCT: Immediate oral refeeding in patients with mild and moderate acute pancreatitis.

22 Jul, 2021 | 10:32h | UTC

Immediate Oral Refeeding in Patients With Mild and Moderate Acute Pancreatitis: A Multicenter, Randomized Controlled Trial (PADI trial) – Annals of Surgery (link to abstract – $ for full-text)

 


Cohort study: Sickle cell disorders and severe COVID-19 outcomes – “Our analysis estimated a 4-fold increased risk for COVID-19–related hospitalization and a 2.6-fold increased risk for COVID-19–related death for sickle cell disease”.

21 Jul, 2021 | 10:44h | UTC

Sickle Cell Disorders and Severe COVID-19 Outcomes: A Cohort Study – Annals of Internal Medicine

 


RCT: Central venous access devices (Hickman catheters vs. PICCs vs. PORTs) for the delivery of systemic anticancer therapy – “PORTs are more effective and safer than both Hickman and PICCs”.

21 Jul, 2021 | 10:42h | UTC

Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial – The Lancet (link to abstract – $ for full-text)

News release: Study highlights more effective and safe way to deliver chemotherapy – University of Glasgow

 


Expert review | Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy.

21 Jul, 2021 | 10:37h | UTC

Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy – American Journal of Obstetrics & Gynecology

 

Commentary on Twitter

 


EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis.

21 Jul, 2021 | 10:35h | UTC

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – Journal of Hepatology – European Association for the Study of the Liver

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.